Navigation Links
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. Arena is finishing a complete analysis of the data, but does not anticipate any further development of APD125.

"While we are disappointed and anticipated a different result based on objective polysomnographic results from our previous studies, our priority remains the successful development of lorcaserin, our proprietary investigative treatment for obesity. We expect to announce lorcaserin results from BLOOM, our first pivotal Phase 3 clinical trial, around the end of March and to file a New Drug Application for lorcaserin by the end of 2009," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the opportunity to review our lorcaserin program, as well as other programs, at our upcoming R&D Day on December 15."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Critical Pharmaceuticals Enter Sustained Release hGH Arena
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
8. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... NOTTINGHAM, England , Oct. 1, 2014 ... today announced that its subsidiary, Molecular Profiles Ltd., is ... at the annual CPhI/ICSE Worldwide event in ... companies with the rapid development of both standard and ... screening platform, which incorporates the company,s existing formulation and ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it ... Teleneurology services. Dr. Ricardo Garcia-Rivera , Founder and ... proud that our quality of service has been recognized ... lifesaving support and continuity of care to patients of ... the United States ." NeuroCall ...
(Date:10/1/2014)... DIEGO , Oct. 1, 2014   Cypher ... the appointment of J. Patrick Ravenel as ... of enterprise software and systems experience and a proven ... 500 companies. "Patrick has been recognized ... software and systems and is known industry-wide for delivering ...
Breaking Medicine Technology:Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 2Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI 3NeuroCall Awarded Joint Commission Accreditation 2Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2
... DIEGO, Dec. 5 Orexigen(R) Therapeutics, Inc.,(Nasdaq: ... resources,focus its efforts on its late-stage obesity programs and ... The key aspects of these changes are as ... The exploratory proof-of-concept Phase 2 trials for OREX-003,(zonisamide ...
... Kiadis,Pharma announces today that it has successfully completed ... I/II clinical trial. ATIR(TM), a donor,lymphocyte cell based ... Host Disease (GvHD) and allow early immune reconstitution ... blood cancer,patients were treated with no cases of ...
Cached Medicine Technology:Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations 2
(Date:10/1/2014)... adage that encourages people to keep their "eyes on ... to exercise. When walking, staying focused on a specific ... shorter and help people walk there faster, psychology researchers ... walking while looking around the environment naturally, offers a ... "People are less interested in exercise if physical activity ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
(Date:10/1/2014)... 2014 First Warning Systems, a pioneer ... changes throughout the body, announced the company is changing ... the company’s breadth of upcoming product releases. The initial ... technology. , “Our initial focus will be an ‘Internet ... abnormal circadian cellular changes over time,” said Rob Royea, ...
(Date:10/1/2014)... October 01, 2014 Farmington Company ... a redefined mission and visual identity helping brokers, ... partnering with them to create greater benefit communication ... that focuses on empowering customers to better leverage ... The crown jewel of the rebrand is the ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
Breaking Medicine News(10 mins):Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Farmington Company Launches Rebrand and New Positioning 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3
... an interesting,snapshot of Minnesotans, changing driving habits, retail ... percent decline compared to sales in July 2007.,According ... motorists,bought 211,982,582 gallons of gasoline in July, compared ... the amount of ethanol-based,E85 sold during the same ...
... medical student in the country. That,s because the three-part ... delivered in a new way: by listening to a ... an Achilles heel in the medical field. , ... test know they don,t have this auditory skill," says Michael ...
... Trevino, master permanent make-up artist and educator joins Nouveau Cosmetique ... advance the education of permanent cosmetic professionals in the US. ... ... August 25, 2008 -- Nouveau Cosmetique USA, Inc., the exclusive ...
... (PTCB) Exhibits at this week,s National Association of Chain Drug ... solutions for enhanced patient safety and the benefits of pharmacy ... ... CA (PRWEB) August 25, 2008 - The https://www.ptcb.org/ ...
... HMS Holdings Corp. (Nasdaq:,HMSY) today announced that it ... which will be held September 3-5, 2008 at the,Four ... and Chief Financial Officer of HMS Holdings Corp.,will present ... A live broadcast of the Company,s presentation can ...
... 96 on the, 2008 Inc. 500, with three-year sales growth ... ... Inc. magazine today ranked The,Coding Source No. 96 on its 27th ... list is the most,comprehensive look at the most important segment of the ...
Cached Medicine News:Health News:Listen up! 2Health News:Master Permanent Make-up Artist and Educator Sulema Trevino Joins Nouveau Cosmetique Team 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 2Health News:Pharmacy Technician Certification Board (PTCB) Exhibits at 2008 NACDS Pharmacy & Technology Conference 3Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 2Health News:The Coding Source Named to Inc. Magazine's 27th Annual List of America's 500 Fastest-Growing Private Companies 3
... Bringing together the best of both ... intraocular instrument is the latest addition ... lightweight Eraser bipolar cautery instruments for ... hemostasis with extrusion aspiration and backflush ...
...
...
...
Medicine Products: